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Progress in characterising the humoral immune response to Severe Acute Respiratory Syn-
drome 2 (SARS-CoV-2) has been rapid but areas of uncertainty persist. Assessment of the
full range of evidence generated to date to understand the characteristics of the antibody
response, its dynamics over time, its determinants and the immunity it confers will have a
range of clinical and policy implications for this novel pathogen. This review comprehen-
sively evaluated evidence describing the antibody response to SARS-CoV-2 published from
01/01/2020-26/06/2020.
Methods
Systematic review. Keyword-structured searches were carried out in MEDLINE, Embase
and COVID-19 Primer. Articles were independently screened on title, abstract and full text
by two researchers, with arbitration of disagreements. Data were double-extracted into a
pre-designed template, and studies critically appraised using a modified version of the Pub-
lic Health Ontario Meta-tool for Quality Appraisal of Public Health Evidence (MetaQAT) tool,
with resolution of disagreements by consensus. Findings were narratively synthesised.
Results
150 papers were included. Most studies (113 or 75%) were observational in design, were
based wholly or primarily on data from hospitalised patients (108, 72%) and had important
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methodological limitations. Few considered mild or asymptomatic infection. Antibody
dynamics were well described in the acute phase, up to around three months from disease
onset, but the picture regarding correlates of the antibody response was inconsistent. IgM
was consistently detected before IgG in included studies, peaking at weeks two to five and
declining over a further three to five weeks post-symptom onset depending on the patient
group; IgG peaked around weeks three to seven post-symptom onset then plateaued, gen-
erally persisting for at least eight weeks. Neutralising antibodies were detectable within
seven to 15 days following disease onset, with levels increasing until days 14–22 before
levelling and then decreasing, but titres were lower in those with asymptomatic or clinically
mild disease. Specific and potent neutralising antibodies have been isolated from conva-
lescent plasma. Cross-reactivity but limited cross-neutralisation with other human coronavir-
idae was reported. Evidence for protective immunity in vivo was limited to small, short-term
animal studies, showing promising initial results in the immediate recovery phase.
Conclusions
Literature on antibody responses to SARS-CoV-2 is of variable quality with considerable
heterogeneity of methods, study participants, outcomes measured and assays used.
Although acute phase antibody dynamics are well described, longer-term patterns are much
less well evidenced. Comprehensive assessment of the role of demographic characteristics
and disease severity on antibody responses is needed. Initial findings of low neutralising
antibody titres and possible waning of titres over time may have implications for sero-surveil-
lance and disease control policy, although further evidence is needed. The detection of
potent neutralising antibodies in convalescent plasma is important in the context of develop-
ment of therapeutics and vaccines. Due to limitations with the existing evidence base, large,
cross-national cohort studies using appropriate statistical analysis and standardised sero-
logical assays and clinical classifications should be prioritised.
Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the novel viral pathogen that
causes coronavirus disease 2019 (COVID-19) in humans, has spread worldwide since its iden-
tification in late 2019. At the time of writing, there have been around 57.9m confirmed cases
and 1.4m deaths reported to the WHO [1]. Limited pre-existing immunity is assumed to
account for the extraordinary rise in cases worldwide. Characterisation of the human antibody
response to SARS-CoV-2 infection is vitally important to inform vaccine development and
strategies, and to guide appropriate design, implementation, and interpretation of serological
assays for surveillance purposes. Transmission models used to predict the behaviour of the
pandemic and plan non-pharmaceutical interventions assume a degree of protective immunity
arising from infection with SARS-CoV-2 [2, 3]. A range of clinical and policy interventions to
tackle SARS-CoV-2 spread depend on better understanding of the dynamics and determinants
of humoral immunity to this virus. These include the proposed use of ‘immunity passports’, a
form of certification for individuals with positive detection of antibodies that can enable them
to avoid isolation or quarantine on the assumption they are protected against re-infection [4];
treatment options such as infusion of convalescent plasma or derived immunoglobulin [5];
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sero-surveillance to monitor progression of the epidemic in the population [6]; and the nature
of the likely response to vaccination and supporting decisions on prioritising use of vaccines.
Experience with other human coronavirus species (HCoV) suggests that partial immunity
arises following infection with a variable but generally short (one to two year) duration [7].
Limited data available for the closely related Severe Acute Respiratory Syndrome Coronavirus-
1 (SARS-CoV-1) indicate that antibodies able to block viral infection (neutralising antibodies)
may persist for up to 17 years following infection [8]. Early clinical studies suggest that the
dynamics of antibody response following acute infection with SARS-CoV-2 is similar to other
HCoVs. Antibody responses are generally detected against the nucleocapsid (N) or spike (S)
proteins, the S1 subunit of which contains the receptor-binding domain (RBD): antibodies
against different antigens may have differential dynamics and neutralising effect. The presence
of neutralising antibodies (nAb) has been demonstrated in studies of vaccine research and
therapeutic use of convalescent plasma [7, 9]. Previous lessons from SARS-CoV-1, Middle
Eastern Respiratory Syndrome (MERS-CoV) epidemics and other seasonal human coronavi-
ruses suggest that there is the potential for a decline in population level protection from rein-
fection over a short period of time, but this is somewhat dependent on initial disease severity
[7, 9]. nAbs are likely to be a key metric for protection against infection by viruses such as
SARS-CoV-2. However, their dynamics and role in long-term population immunity are not
well understood [7]. Furthermore, understanding of the mechanistic correlates of protective
immunity in humans remains limited, including the antibody titre and specificity required to
confer protection [10].
This is the first of two linked papers reporting results from a systematic review of peer-
reviewed and pre-print literature on the immune response to SARS-CoV-2 infection [11]. This
paper has three aims. Firstly, to characterise the antibody response to SARS-CoV-2 infection
over time and explore the effects of potential correlates of immune activity (including age,
time since symptom onset, clinical severity and ethnicity) on the nature of this response. Sec-
ondly, to consider relationships between these variables and indirect or relative quantification
of antibodies to SARS-CoV-2. Thirdly, to consider the duration of post-infection immunity
conferred by the antibody response.
Materials and methods
This systematic review was carried out according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines. The protocol was pre-registered with
PROSPERO (CRD42020192528).
Patient and public involvement
There was no patient or public involvement in the conceptualisation or design of this review.
Identification of studies
Keyword-structured searches were performed in MEDLINE, Embase, COVID-19 Primer and
the Public Health England library [12] for articles published from 01/01/2020-26/06/2020. A
sample search strategy is in S1 Appendix in S1 File. Subject area experts were consulted to
identify relevant papers not captured through the database searches.
Definitions, inclusion and exclusion criteria
We included studies in all human and animal populations, and in all settings (laboratory, com-
munity and clinical—encompassing primary, secondary and tertiary care centres) relevant to
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our research questions. We excluded the following study designs: case reports, commentaries,
correspondence pieces or letter responses, consensus statements or guidelines and study
protocols.
We focused on studies reporting measured titres (total antibody, IgA, IgG and/or IgM)
with follow-up duration of greater than 28 days (which we defined as the limit of the acute
phase of illness). Shorter follow-up studies were included if they reported on protective immu-
nity, or immune response correlates. We defined “correlates” as encompassing, among other
factors: primary illness severity—proxied by the WHO’s distinction between “mild”, “moder-
ate”, “severe” and “critical” illness [13]; subject age; gender; the presence of intercurrent or co-
morbid disease e.g. diabetes, cardiovascular and/or chronic respiratory disease; and ethnicity.
Selection of studies
Studies were independently screened for inclusion on title, abstract and full text by two mem-
bers of the research team (working across four pairs), with arbitration of disagreements by one
review lead.
Data extraction, assessment of study quality, and data synthesis
Data were extracted in duplicate from each included study. Extraction was performed directly
into a dedicated Excel template (S2 Appendix in S1 File). Pre-prints of subsequently published
peer reviewed papers were included and results extracted where substantial differences in
reported data were identified; if little difference was observed only the peer-reviewed version
was retained.
Critical appraisal for each included study was performed in duplicate using a version of the
MetaQAT 1.0 tool, adapted for improved applicability to basic science and laboratory-based
studies. MetaQAT was selected for its simplicity and versatility in application to studies of all
design types [14]. Principal adaptations to the MetaQAT tool are described in S3 Appendix in
S1 File.
The adapted MetaQAT tool was used to gather both qualitative (narrative) feedback on
study quality and scaled responses (yes/no/unclear) for answers to key questions around study
reliability, internal and external validity, and applicability, among other fields. These data pro-
vided the basis for quality assessments for each paper included in the review.
Study heterogeneity precluded formal meta-analysis. Results were instead synthesised
narratively.
Ethical approval
This was a systematic review based on analysis of openly published secondary data and did not
involve humans. No ethical approval was required.
Results
The PRISMA flowchart for the review is given in Fig 1.
General characteristics of included studies
150 studies were included, of which 108 (72%) contained data pertaining to antibody response,
and 70 (47%) to protective immunity (descriptive statistics for included studies are given in
Table 1). The vast majority (108 or 72%) focused on hospitalised patients (i.e. higher severity
disease). Eleven studies (7%) considered antibody responses in asymptomatic individuals in
the community and only five (3%) investigated protective immunity in this group. Most
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studies had significant methodological limitations. Assays used to detect and quantify antibody
response were diverse, with target antigens including spike (S), S1 and S2 subunits, receptor
binding domain (RBD) and nucleocapsid (N). Details of assays used, and an overview of
strengths and limitations of these is provided in S4 Appendix in S1 File.
Kinetics of the antibody response
Time to seroconversion. The majority of individuals in the included studies mounted a
SARS-CoV-2-specific antibody response during the acute phase of illness, with many studies
reporting 100% seroconversion. Overall seroconversion rates depended on the time point at
Fig 1. PRISMA flowchart describing the process of screening and selection of included studies.
https://doi.org/10.1371/journal.pone.0244126.g001
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which testing was conducted in the disease course, the populations under study, the serology
assay platforms used and their specific target proteins. Studies considered time to seropositiv-
ity for total antibody and/or individual antibody classes (IgA/IgG/IgM) (Fig 2), although this
was often not clearly defined with respect to symptom onset or first positive PCR test. In addi-
tion, whilst some studies described specific target proteins of assays used, others were either
non-specific or not described. This limited assessment of dynamics of antibodies against spe-
cific viral targets, in particular anti-N versus anti-S, the latter of which may be more closely
related to protection.
A number of studies reported seroconversion for total antibody (combined IgG, IgM and/
or IgA) [15–21], however the focus of findings presented is for specific antibody isotypes. For
IgG, mean or median time to seroconversion ranged from 12–15 days post symptom onset [7,
9, 15, 22–26], with wide variation in first to last detection of IgG from four to 73 days post
Table 1. Summary of characteristics of included studies.
Antibody response Protective Immunity All papers
Article type
Pre-print 57 43 81
Peer reviewed paper 51 26 68
Report 0 1 1
Study designs
Cohort 58 18 66
Case control 20 14 26
Case series 15 8 21
Basic science 4 22 24
Narrative review 4 2 4
Systematic review with meta-analysis 5 2 5
Systematic review without meta-analysis 1 1 1
Non-randomised trial 1 2 3
Subjects
Human 104 58 137
Animal 1 6 6
Both 3 6 7
Country of origin
China 41 20 54
USA 15 14 21
Europe excl UK 29 9 35
UK 7 5 10
Other countries 5 4 7
Multiple populations 10 6 11
Lab or animal based� 1 12 12
Study setting
Hospital patients 70 33 85
Mixed hospital and community 18 11 24
Community 13 5 18
Unclear 6 12 14
Animal only study 1 9 9
Note that some studies addressed both Ab and protective responses, and hence are counted in both of the columns
relating to these topics above.
https://doi.org/10.1371/journal.pone.0244126.t001
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symptom onset although reporting methods varied by study [15, 27–33]. For IgM, mean or
median time to seroconversion ranged from four to 14 days post symptom onset [7, 9, 15, 22–
24, 26, 31, 34], again with variations in reporting methods, study quality, and sample size giv-
ing rise to uncertainty around findings. Time to seroconversion for IgA was measured in
fewer studies, ranging from four to 24 days post symptom onset, although most were within
four to 11 days [23, 35, 36], with some outliers, including two reports of 24 days to first detec-
tion [37, 38].
Sequential antibody response. In line with the expected sequential appearance of anti-
body isotypes, the majority of studies reported detection of IgM followed by IgG [15, 23, 39,
40]. Nevertheless, this finding was not consistent across all studies. One study measured time
to seroconversion for IgA, IgM, and IgG and demonstrated detection of IgA and IgM simulta-
neously, followed by IgG [23]. One study detected IgG seroconversion in advance of IgM [26],
and a study involving African green monkeys reported simultaneous IgM and IgG responses
[41]. These disparities may reflect the use of differing antibody assays across a range of species
and without standardisation.
Antibody dynamics over time. IgG dynamics appeared to follow a pattern of peak, pla-
teau, and persistence at lower levels (Fig 3). After appearance, IgG titres rose to a peak between
Fig 2. Forest plot of median time to seroconversion by severity across included studies. Central points in the forest plot represent the median reported by each
study overall. Included studies reported the distribution of times to seroconversion around the median in different ways: lines with whiskers represent ranges (from
maximum to minimum around the median); lines without whiskers represent interquartile ranges around the median; for a small number of studies only point
estimates were provided.
https://doi.org/10.1371/journal.pone.0244126.g002
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three and seven weeks post symptom onset [7, 23, 30, 42–48], with studies recording the pres-
ence of IgG in and beyond weeks four [40, 49], five [50], six [23, 51], seven [52, 53], and eight
[17, 45, 54–56] post symptom onset. Some studies reported a plateau in virus-specific IgG
beyond week three but levels beyond the peak were not well described [32, 57–59]. A decrease
in antibody levels was reported in the eighth week post symptom onset by two studies [17, 38],
while another reported a decline from the second month after symptom onset [58]. Evidence
from a cohort of 40 UK patients suggests a decline in titres after eight weeks [58], although per-
sistence of virus-specific IgG has been described at varying levels up to 12 weeks post symptom
onset [43], the longest follow up period among included studies. Dates of last detection were
limited by the length of the study follow-up period, rather than confirmation of disappearance
of detectable antibody titres.
IgM dynamics follow a ‘rise and fall’ pattern, with a peak two to five weeks post symptom
onset [7, 26, 30, 34, 43, 46, 47, 53, 60] then decline over time to below the detection limit [38,
43, 61]. Beyond the peak, IgM is consistently reported to decrease from as early as two to three
weeks [53, 60], to as late as eight weeks [55] post symptom onset, with the majority of studies
reporting this decline to occur at between three to five weeks [40, 43, 61, 62]. Virus-specific
IgM became undetectable in almost all cases by around six weeks after disease onset in two
small but well-conducted cohort studies [53, 63].
Fewer studies describe IgA dynamics compared to IgM or IgG. IgA levels are reported to
peak between 16–22 days post symptom onset, although there is no consensus on trends over
time [23, 60].
Correlates of antibody response
Key findings regarding correlates of the antibody response to SARS-CoV-2 infection are sum-
marised in Table 2. Included papers addressed clinical factors (disease severity, co-morbid
disease status and symptom profile) and demographic factors (age, sex and ethnicity) although
results for many of these factors were conflicting or inconclusive. Across all papers, the defini-
tions of comparator groups were highly variable, including disease severity classifications
(severe/mild), outcomes (deceased/mild), and treatment categories (ICU/Non-ICU). The lack
of consistency in methods, comparison groups and study design means it is not possible to
Fig 3. Schematic showing the scale of IgG/IgM/IgA/Neutralising Ab response over time from disease onset. Note
that the y-axis is illustrative only and therefore no scale is given: this figure gives an indicative overview of findings
from all included studies with relative peaks and decline indicated.
https://doi.org/10.1371/journal.pone.0244126.g003
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Table 2. Summary of evidence on correlates of antibody response from studies included in this review.





Longitudinal trends in Ab
production
• Most studies report no relationship between time to seroconversion for IgG or IgM and disease
severity [22, 30, 35, 53, 56, 64].
• A number of studies report earlier antibody response to more severe disease, including specifically for
IgG [7]; a shorter time to peak antibody titre [19, 65–67], and that IgG and IgM persist for longer in
severe disease compared to milder cases [68, 69].
• Conversely, several studies report an earlier antibody response to milder disease [26, 43], including
specifically for IgM [70] and IgA [69, 71]. One study reported shorter time to peak for IgG in mild
cases [69], and another reported IgG persisting for longer compared to severe cases [72].
• One study reports lower seroconversion rate amongst asymptomatic compared to symptomatic cases
[73].
• Two other studies on this association were limited by lack of detail on methodology and participant
selection [74, 75].
Antibody titre • Ten studies reported that more severe cases have higher IgG titres [23, 34, 39, 42, 62, 76–80], three
studies reported no difference between mild and severe cases [44, 52, 81].
• Five studies reported severe cases have higher IgM titres [23, 34, 39, 45, 53], two studies reported no
difference in between mild and severe cases [63, 81], and three studies reported severe cases have
lower IgM titres [80, 82, 83].
• Three studies report severe cases have higher IgA titres [23, 69, 78], one study reports no difference
between mild and severe cases [82].
Co-morbid
disease
• Two studies report an association between co-morbidities and seroconversion or antibody positivity
[63, 84], with one finding immunocompromised individuals developed a lower response [85].
• One study reports antibody responses to be independent of co-morbidities, for both IgA and IgG [78].
• One study on this association was limited by sampling bias leading to low quality [86].
Symptom
profile
• Several studies report an association between COVID-19 symptoms and: seropositivity [87–89],
higher titres of IgG [29, 79, 90] and anti-RBD and anti-S antibodies [91].
• Two studies reported that asymptomatic healthcare workers did develop antibodies [92, 93].
• Fever appears to have a consistent relationship with seropositivity and antibody titres [29, 89, 91],
although other symptoms such as ageusia have also been associated [87, 89].
Demographic Sex • Four studies report no association between antibody titres (either IgG or IgM) and sex [21, 78, 94, 95].
• One study reports a higher IgG titre in women, in ‘severe’ patients only [96].
• One study reports a delayed peak of antibody response in men [97].
• Two studies report a higher proportion of women tested positive for antibodies [87, 95].
• One study found higher anti-RBD and anti-S antibodies in male plasma donors [91]. Another study
found higher concentrations of IgM in male cases [34].
Age Older adults • Five studies found no association between antibody response and age, for both antibody positivity [63]
or IgM/IgG titre [21, 58, 78, 98].
• One study found that seroconverters were older than non-seroconverters [84] and another that the
concentration of IgG was related to age [34].
• Three studies reported that older people had higher titres of IgA and IgG [23], IgM [94], and anti-S
and anti-RBD IgG [91].
Children • Two studies found children generally developed a detectable antibody response to SARS-CoV-2
infection [99, 100].
• Two studies found children with pneumonia generally mounted lower IgG [101] and IgA responses
[102].
• One study found no significant difference between the levels of antibody in children and adults [98].
• Two studies reported most neonates born to COVID-19 positive mothers had raised IgM [103, 104],
and COVID-19 recovered donor breast milk was found to have reactive IgA in one study [105].
Ethnicity • One study reported non-white ethnicity was associated with higher antibody levels than white
ethnicity [84].
https://doi.org/10.1371/journal.pone.0244126.t002
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determine whether or how disease severity affects, or is affected by, the antibody response.
Most studies showed no association between antibody response and age or sex, and, when
taken together, studies that did show associations had inconclusive results and lacked statistical
analysis to relate these findings to disease severity. There were virtually no data to describe the
immune response according to ethnicity.
Protective immunity
Neutralising antibody kinetics. Across the included studies, the majority of subjects
developed detectable neutralising antibodies in response to SARS-CoV-2 infection in both
human [7, 18, 22, 29, 76, 100, 106–127] and animal [41, 128–131] participants. However, neu-
tralising antibody titres were low in a substantial minority of participants. A small although
relatively robust cohort study found almost all participants (94%, n = 19) generated an anti-
body response capable of neutralising 42–99% of pseudovirus in a carefully validated assay 14
days after exposure [124]. Another well conducted cohort study also found most patients
(91%, n = 22) developed a neutralising antibody response by 21 days after disease onset [125].
However only three quarters developed titres over 1:80. A larger case-control study including
a sample of largely non-hospitalised convalescent patients demonstrated most participants
(79%, n = 149) had low neutralising antibody titres (<1:1000) after an average of 39 days fol-
lowing disease onset, while only 3% showed titres >1:5000 [127]. Notably, RBD-specific anti-
bodies with potent antiviral activity were found in all individuals tested, suggesting specific
neutralising antibodies are produced following infection despite low overall plasma neutralis-
ing ability [127].
Neutralising antibodies were generally detectable between seven to 15 days following dis-
ease onset [7, 18, 76, 106, 125, 126, 132, 133], increasing over days 14–22 before plateauing [22,
106, 110, 111, 132, 133] and declining over a period of six weeks [106, 111, 126, 134]. Evidence
from one pre-print study suggests neutralising antibody titres reduced significantly among 27
convalescent patients around six weeks following disease onset to a mean neutralisation half
maximum inhibitory dilution (ID50) of 596 [51] although this study was at risk of bias due to
minimal reporting on methods used for participant selection. A second preprint study, also
limited by lack of reporting on inclusion criteria, found neutralising antibodies became unde-
tectable in four of 11 previously detectable cases [126]. Further high-quality evidence is
required to fully evaluate the apparent waning of the neutralising antibody response over
time. To date no studies have determined neutralising titres in upper respiratory tract samples.
Correlates of neutralising antibody production. Clinical and demographic correlates of
the neutralising antibody response are described in Table 3. Neutralising antibody responses
correlated with disease severity in all studies in which this association was tested [7, 43, 49,
108, 117, 126, 127, 135–137]. Importantly, the few studies that investigated asymptomatic
cases found those individuals were considerably less likely to develop detectable serum neutral-
ising antibody responses than cases with symptoms. With regard to age and sex, evidence was
mixed and a limitation across all papers was a lack of statistical adjustment for severity.
Correlation of neutralisation with specific antibodies. The level of neutralisation was
found to correlate with a wide range of specific antibodies. Most studies suggested that neutra-
lisation ability broadly correlated with total virus-specific IgG [29, 49, 109, 116, 127, 138–140].
Specifically, a number of well-conducted studies found that neutralisation ability correlated
positively with anti-S IgG [49, 114, 127, 138] or anti-RBD IgG [81, 114, 116, 127]. There was
more limited evidence for correlation with anti-RBD IgM and IgA in peer reviewed studies
with appropriate statistical analyes [51, 125, 132, 138].
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A number of basic science studies also identified specific neutralising antibodies. The
majority of these studies were of variable but moderate quality, and heterogeneity between
assays limits comparability of findings. A well-conducted basic science study by Rogers et al
highlighted the important role of RBD binding antibodies in neutralisation in a pseudovirus
assay, with findings supported by an effective animal re-challenge model [141, 142]. This study
also reported that SARS-CoV-2 infection elicited a strong response against the S protein. How-
ever, few of these antibodies were neutralising, in agreement with other results [143, 144].
RBD-specific antibodies were also shown to have potent neutralising activity in a range of
other small studies [112, 143, 145–151], including one using an IgA isotype [152]. Neutralising
ability correlated in particular with competition for the angiotensin converting enzyme-2
(ACE2) receptor [112, 114, 145]. Two studies demonstrated a lack of association with affinity
[115, 145], although a moderate correlation with binding affinity was reported in one study
[146]. Potently neutralising N specific antibodies were isolated in other studies [115, 148], and
the potential for antibodies binding to protease cleavage sites as alternatives to RBD isolated
from convalescent plasma has also been identified [153], suggesting an important role in pre-
venting antibody dependent enhancement of viral entry.
Few studies investigated B cell responses in detail. A study by Galson et al of 19 hospitalised
patients demonstrated clonal expansion and induction of a B cell memory response (possibly
to other circulating coronaviridae) but that the predominant expansion was in the naïve B
cell population [154]. Strong convergence of response emerged across different participants,
which was judged to be associated with disease severity, and these findings were consistent
with a large and well conducted case control study by Robbiani et al [127].
Correlation of antibodies with viral load. Several studies investigated the relationship
between SARS-CoV-2-specific IgG and viral load [155, 156] or the co-existence of antibodies and
viral RNA [15, 24, 25, 38, 42, 46, 61, 63]. In a large cohort study, the presence of SARS-CoV-2
anti-N IgG was significantly correlated with reduced viral load (measured as cycle threshold (Ct)
>22, which was also associated with lower mortality) [155]. This was consistent with a study by
To et al which correlated increasing anti-N IgG titres with decreasing median viral load from 6.7
Table 3. Summary of evidence on correlates of neutralising antibody response from studies included in this review.
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• One study reported asymptomatic cases with neutralising antibodies were more likely to lose detectable
neutralising antibodies in the convalescent phase [90].
Antibody titre • Ten studies reported a higher titre of neutralising antibodies in more clinically severe cases [7, 43, 49,
108, 126, 127, 134–137].
• One study reported undetectable neutralising activity in plasma from a majority of asymptomatic cases
[126].
Demographic Sex N/A • Five studies reported neutralising antibody response was positively correlated with male sex [108, 110,
127, 135], although it is unclear how this is related to disease severity [49].
• One study reported a positive correlation between neutralising antibody formation and female sex
[126].
Age Older adults • Two studies reported increasing neutralising antibody response with increasing age [20, 133].
• Two studies reported no association between neutralising antibodies and age [110, 126].
Children • Two studies reported children can develop a neutralising antibody response [48, 100].
Ethnicity N/A • One study reported that individuals with Hispanic/Latino ethnicity were more likely to have detectable
neutralising antibody responses (although this study was based on a convenience sample in an atypical
cohort—US service personnel on a warship) [107].
https://doi.org/10.1371/journal.pone.0244126.t003
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to 4.9 log10 copies per mL between weeks one to three [156]. Another relatively large cohort
study including controls had similar findings but did not quantify viral load [24]. Together these
findings suggest the persistence of detectable RNA despite clinical recovery, and although viral
loads generally reduced in the convalescent phase, co-existence of SARS-CoV-2 specific IgG and
detectable SARS-CoV-2 RNA could be identified in a small number of patients for up to 50 days
following seroconversion [25]. Other studies were mixed, with one finding higher levels of spe-
cific antibodies correlated with viral clearance within 22 days [38], and another finding weaker
IgG response correlated with viral clearance within seven days after antibodies become detectable
[42], although both of these findings are subject to a number of limitations. Importantly, one
included study attempted to associate re-detection of viral RNA with the presence of specific
antibodies, finding that IgG titres began to decrease immediately following recovery although
this was not associated with whether RNA was re-detected. Across all included studies, high
quality evidence for re-infection or lasting immunity was lacking.
Re-exposure to SARS-CoV-2. Studies exploring re-exposure to SARS-CoV-2 virus were
limited to seven animal studies of variable quality. Broadly, two areas were explored; exposure
following a primary infection with SARS-CoV-2 [128–130, 157] and re-exposure following
passive transfer of neutralising antibodies [130, 141, 142].
Following primary infection, timing of re-challenge varied between 20–43 days post inocu-
lation. All studies but one [129] demonstrated some level of protection from reinfection with a
study in nine macaques showing a significant reduction in viral titres (p<0.001) and reduced
clinical symptoms [128]. Similar findings were reported in a hamster model [131, 157]. In a
smaller ferret study, clinical findings following reinfection were mixed with the re-challenged
group demonstrating increased weight loss compared to naive ferrets. However, the authors
acknowledged that the sample size (n = 4) was too small to draw wider inference [129].
Two studies examined protection from SARS-CoV-2 infection following the passive trans-
fer of neutralising antibodies in Syrian hamster models [130, 141, 142]. Following transfer of
highly potent neutralising antibodies 12 hours prior to infection, hamsters showed lower viral
titres and fewer clinical symptoms of COVID-19. However, following transfer of less potent
neutralising antibodies, one to two days prior to infectious challenge, results were mixed dem-
onstrating their inability to fully neutralise the virus [141]. Data on protection from re-infec-
tion in humans was not identified in the included papers, therefore conclusions on protective
immunity are limited.
Cross-reactivity with other coronaviruses. There is limited evidence on the cross-reac-
tivity of antibodies specific to other coronaviruses [8, 49, 51, 133, 158, 159]. Using a variety of
assays, several in-vitro studies explored both cross-reactive antibody-binding responses and
cross-neutralisation between SARS-CoV-2 and seasonal HCoVs, MERS-CoV and SARS-CoV-
1. Cross-reactive antibody-binding responses appear to be highest between SARS-CoV-1 and
SARS-CoV-2, however cross-neutralisation is rare and where reported is weak [49, 133, 158].
Whilst seasonal HCoVs are more common in the population, only 10% of sera exposed to
HCoVs demonstrated cross-reactivity again with very little neutralisation activity [159]. A
study comparing cross reactivity in children and older participants found children had ele-
vated CoV-specific IgM compared to more mature class-switched specific IgA and IgG [160].
All studies were performed in-vitro and recognised the need for in-vivo investigation.
Discussion
Summary of findings
This review narratively synthesis the findings from 150 studies published by the end of June
2020. The pace of production of evidence over time in regard to SARS-CoV-2 has been
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exceptional, and further evidence is now available with which to contextualise these earlier
contributions to our understanding of SARS-CoV-2 infection. In the discussion that follows
we summarise key findings from the included studies and highlight in addition (where rele-
vant) evidence published since our searches were completed.
Most people who experience symptomatic SARS-CoV-2 infection undergo seroconversion
to produce a detectable, specific antibody response in the acute phase (�28 days). The kinetics
of the antibody response to SARS-CoV-2 follow typical immunological paradigms: virus-spe-
cific IgM rises in the acute phase to a peak around two to five weeks following disease onset,
then declines over a further three to five weeks before becoming undetectable in many cases;
IgG peaks later (three to seven weeks following disease onset), then plateaus, persisting for at
least eight weeks with some evidence suggesting a moderate decline over that period. However,
understanding of IgG dynamics over time is limited by the understandably short duration of
follow up in studies published for inclusion in this review. Studies with longer follow are now
be starting to show persistence of IgG for at least three to four months [161, 162].
Evidence suggests the majority of those infected with SARS-CoV-2 develop nAbs—a find-
ing consistent with that for SARS-CoV-1 and MERS-CoV [7]. The magnitude of this response
appears to correlate with disease severity, although not necessarily the kinetics. Neutralising
antibodies are initially detectable from around seven to ten days, peaking at around three
weeks and then declining. Further evidence is required to evaluate comprehensively the appar-
ent waning of the nAb response over time: in the studies included here although nAb may be
detectable, higher quality studies suggest that titres are generally low, and the response is short
lived. Although this is supported by recently published data (beyond the date cut off for inclu-
sion in this study) from a UK cohort of healthcare professionals with follow up to three months
[163], durable neutralising antibody response up to seven months have now been described
[164]. Ongoing vaccine research has highlighted a need for evidence of longer-term protection
due to nAbs, and the titres at which these effects are achieved—neither of which were fully
addressed by studies included in this review. A number of potent, specific nAbs have been
identified—in line with findings for other HCoVs. This is particularly the case for neutralising
anti-RBD antibodies [165], and is consistent with data emerging from vaccine development
studies showing that protective antibodies can be induced [166–168].
Data on correlates of the antibody response in this review were incomplete, inconsistent or
contradictory. It is not possible to draw robust conclusions on the associations of antibody
response with age, sex, ethnicity or comorbidities, and although disease severity positively cor-
related with higher IgG antibody titres in a number of studies, distinguishing causation from
correlation is not possible. More recent evidence shows that while responses may be of lower
magnitude in milder cases, they are still elicited and may be protective—although evidence on
response patterns in milder illness remains in short supply [164, 169].
The size of the detectable nAb response appears to be associated with male sex (although
the effect of disease severity was not controlled for); this is a surprising finding given the now
well-recognised association between male sex and poor COVID-19 outcomes [170]. A recent
study has characterised sex differences in the cytokine and cellular response, although identi-
fied no differences in anti-S1 IgG or -IgM between male and female cases [171]. With regard
to age, recent data published beyond the cut off for this review has shown distinct antibody
responses in children and adults, which may inform future understanding of the disease course
in different age groups [172]. This is a welcome addition to the literature considering the lack
of studies on children included identified for our review.
Available data on protection following primary infection for this review were limited to
small scale animal models which consider re-exposure rather than reinfection. Primary infec-
tion appears to provide a degree of protection to reinfection up to day 43 post primary
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inoculation but no further data were available at later time points. The success of passive trans-
fer of nAbs for protection against SARS-CoV-2 infection appears to be dose dependent,
although no data exist around the importance of affinity, isotype or immunoglobulin subclass.
Given the possible reduction in nAb titre over time the protection they provide could be lim-
ited. However, more recent evidence from a large cohort of UK health professionals has shown
anti-S IgG generated following natural infection may protect from re-infection up to six
months [173], consistent with emerging data on the durability of neutralising antibodies.
Further evidence on longer durability and correlates is required.
Some emerging evidence has suggested pre-existing humoral immunity arising from infec-
tion with seasonal HCoVs, although these data remains difficult to interpret [159]. Overall,
our review found limited evidence of cross reactivity between SARS-CoV-2 and other HCoVs,
but cross-neutralisation is rare and when it does occur, fails to fully neutralise the SARS-CoV-
2 virus.
Strengths and limitations
This study presents, to our knowledge, the first comprehensive overview and critical appraisal
of studies investigating the antibody response to SARS-CoV-2 infection over the first 6 months
of the pandemic. The results presented here have a range of implications for treatment and
policy, as well as providing a useful basis for building further research. Our findings are never-
theless limited both by aspects of the review methodology and by shortcomings in the included
literature. The comprehensiveness of systematic reviews is always dependent on search strat-
egy, and some results relevant to the research question may have been missed; as with all
systematic reviews, our findings cannot account for unpublished negative results; and impor-
tantly, the pace of evidence production on SARS-CoV-2 means that systematic review research
is inherently at risk of missing new, divergent data.
Limitations of the underlying evidence base were considerable. A majority of included stud-
ies were of variable but generally moderate quality. Study populations were highly variable, as
were the assays used, along with the rigour with which they were described, verified and vali-
dated against their target populations. There are efforts in the UK to standardise laboratory
SARS-CoV-2 assays use through the National External Quality Assessment Service (NEQAS),
but these are early stage and no comparable international initiatives yet exist to support com-
parability of research findings. Longitudinal follow-up for durations greater than 50–60 days
was rare, although we note this was limited by the timeline of the review for this novel patho-
gen. Many studies did not perform statistical analysis of findings; in particular, studies of
putative correlates of immune response usually failed to control for the effects of potential con-
founders. Small sample sizes were common, as were study populations selected by convenience
which, although common for clinical cohort studies, are prone to bias. Additionally, a large
body of the evidence drew from pre-print publications which have not been subject to peer-
review. While efforts were made to account for this during synthesis and reporting, reporting
standards in these publications were highly variable and there is no validated system at this
time for weighting evidence from pre-print publications relative to peer-reviewed papers.
Finally, a substantial proportion of included studies failed to appropriately make statements
on ethical approval for studies or the use of consent for participation. There were two underly-
ing factors behind this. First, papers uploaded to pre-print servers routinely failed to include
an ethical statement: although this may be updated by the time of the peer reviewed publica-
tion, the wide use of pre-print material in the current phase of the pandemic suggests ethical
statements should be routinely made in these uploaded manuscripts. Second, a number of
studies where ethical statements were made reported that informed consent for participation
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was waived due to the pandemic situation: such measures limit the confidence with which
such research can be used, particularly in an academic field where the use of informed consent
should be routine, and where the ethical conduct of studies with human subjects should be the
norm.
Implications for policy
We identify two main policy implications arising from this work. At individual level, continu-
ing uncertainty concerning the nature of the humoral response to SARS-CoV-2 makes it diffi-
cult to determine what the practical meaning of serologically-detected antibody response is
with respect to sterilising immunity. Short follow-up periods, as well as the use of binary (posi-
tive/negative) serological tests in many studies continue to limit what can be said about the
granularity of the immune response over time—and by implication, how best to interpret the
results of serological testing with respect to individual susceptibility to infection [174]. We did
not identify any studies considering risk of re-infection with SARS-CoV-2, which might pro-
vide an alternative perspective on susceptibility to infection. Further studies published follow-
ing the completion of this review shed additional light in this area, although this question
remains under active investigation.
At a population-level, important policy implications arising from these data on antibody
response relate to both surveillance and control. Serological tests have been evaluated predom-
inantly in acutely unwell, hospitalised patients (without appropriate validation against mild
disease or in people with asymptomatic infection) and seroprevalence estimates from this
work should therefore be treated with caution. A recent Cochrane review emphasises the risk
of false-positive and false-negative results under different population prevalence scenarios
[175]. However, in the UK, nationally validated assays have been evaluated with convalescent
samples from community participants and a number of large-scale sero-surveys now use these
[176–178]. Clear understanding of the kinetics of the response, particularly for the specific N
and S antigens, is important for the interpretation of seroprevalence studies. Serological tests
remain variable in performance, and a major constraint in interpreting findings across differ-
ent studies.
With regard to control, the evidence here for lasting protective immunity, or lack thereof,
post-infection, may suggest it is too early to recommend the use of ‘immunity passports’. A
range of promising data have been identified to support further investigation of treatment
with convalescent plasma or immunoglobulin. The basic science underlying the antibody/
virus/host cell interaction is starting to be described, with promising findings related to vac-
cine development: most recent vaccine data shows they are able to generate robust humoral
responses [166]. For vaccines strategies for implementation will also require a thorough under-
standing of the likely impact in different population groups. Initial findings presented here
give useful context to this, although further research is needed.
Onward research questions
The limited amount of data on antibody dynamics for mild and asymptomatic cases, which
are likely to make up a significant proportion of infections, is a particularly important gap in
the literature that will need to be addressed to improve understanding and definition of the
varied clinical phenotypes associated with SARS-CoV-2 infection, although progress is starting
to be made in this area. Investigating the relationship between antibody response and corre-
lates including age, sex, ethnicity and disease severity through high-quality, large-sample stud-
ies using well validated assays and incorporating appropriate statistical testing of results
should be prioritised.
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Mutations affecting infectivity and potential resistance to vaccines are an emerging threat.
There has been considerable recent attention on the likely impact of mutations to the S protein
arising from infection in non-human hosts transmitting back to humans. A range of muta-
tions, and their resistance to neutralising monoclonal antibodies, have been characterised
[179]; however, further work in the area will be essential for understanding the roll out of vac-
cines in populations around the world.
Evidence on immunity beyond six months following primary infection or vaccination is
urgently needed. Evidence of immunity following vaccination is being explored through vari-
ous vaccine trials (e.g. ChAdOx1 nCoV-19) [166]. However, further longitudinal studies of
those already infected with SARS-CoV-2 is required to examine the degree of protection aris-
ing from prior infection.
Conclusion
Studies on the immune response to SARS-CoV-2 is of variable quality, and comparison of
findings is difficult. A longer-term view and a more comprehensive assessment of the role of
demographic characteristics and disease severity is required. Larger, high-quality, longitudinal
studies, with appropriate statistical analysis, consistent use of established and well-validated
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68. Candel González FJ, Viñuela-Prieto JM, Del Castillo JG, Garcı́a PB, Saavedra MF, Pı́riz AH, et al. Util-
ity of lateral flow tests in SARS-CoV-2 infection monitorization. Rev Esp Quimioter. 2020; 33(4):258
https://doi.org/10.37201/req/052.2020 PMID: 32492991
69. Carsetti R, Zaffina S, Mortari EP, Terreri S, Corrente F, Capponi C, et al. Spectrum of innate and adap-
tive immune response to SARS CoV 2 infection across asymptomatic, mild and severe cases; a longi-
tudinal cohort study. medRxiv [Preprint]. 2020; 2020.06.22.20137141v1. Available from: https://www.
medrxiv.org/content/10.1101/2020.06.22.20137141v1.full.pdf
70. Shen L, Wang C, Zhao J, Tang X, Shen Y, Lu M, et al. Delayed specific IgM antibody responses
observed among COVID-19 patients with severe progression. Emerg Microbes Infect. 2020; 9
(1):1096–101 https://doi.org/10.1080/22221751.2020.1766382 PMID: 32476607
71. Dahlke C, Heidepriem J, Kobbe R, Santer R, Koch T, Fathi A, et al. Distinct early IgA profile may deter-
mine severity of COVID-19 symptoms: an immunological case series. medRxiv [Preprint].
2020;2020.04.14.20059733. Available from: https://www.medrxiv.org/content/medrxiv/early/2020/04/
17/2020.04.14.20059733.full.pdf
72. Marcos-Jimenez A, Sanchez-Alonso S, Alcaraz-Serna A, Esparcia L, Lopez-Sanz C, Sampedro-
Nunez M, et al. Deregulated cellular circuits driving immunoglobulins and complement consumption
associate with the severity of COVID-19. medRxiv [Preprint]. 2020; 2020.06.15.20131706v1. Avail-
able from: https://www.medrxiv.org/content/10.1101/2020.06.15.20131706v1. PMID: 33251605
PLOS ONE Antibody response to SARS-CoV-2 infection in humans
PLOS ONE | https://doi.org/10.1371/journal.pone.0244126 December 31, 2020 20 / 27
73. Zhang Z, Xiao T, Wang Y, Yuan J, Ye H, Wei L, et al. Early viral clearance and antibody kinetics of
COVID-19 among asymptomatic carriers. medRxiv [Preprint]. 2020;2020.04.28.20083139. Available
from: https://www.medrxiv.org/content/medrxiv/early/2020/05/02/2020.04.28.20083139.full.pdf
74. Dobi A, Frumence E, Rakoto ML, Lebeau G, Vagner D, Seteyen A-LS, et al. Serological surveys in
Reunion Island of the first hospitalized patients revealed that long-lived immunoglobulin G antibodies
specific against SARS-CoV2 virus are rapidly vanishing in severe cases. medrxiv. 2020;
2020.05.25.20112623v1. Available from: https://www.medrxiv.org/content/10.1101/2020.05.25.
20112623v1.
75. Duan L, Zhang S, Guo M, Zhou E, Fan J, Wang X, et al. Epidemiological and clinical characteristics in
patients with SARS-CoV-2 antibody negative probable COVID-19 in Wuhan. medRxiv [Preprint].
2020; 2020.06.18.20134619v1. Available from: https://www.medrxiv.org/content/10.1101/2020.06.
18.20134619v1
76. Perera RAPM, Mok CKP, Tsang OTY, Lv H, Ko RLW, Wu NC, et al. Serological assays for severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Eurosurveillance. 2020; 25
(16):2000421. https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000421 PMID: 32347204
77. Rijkers G, Murk J-L, Wintermans B, van Looy B, van den Berge M, Veenemans J, et al. Differences in
antibody kinetics and functionality between severe and mild SARS-CoV-2 infections. medRxiv [Pre-
print]. 2020; 2020.06.09.20122036v1. Available from: https://www.medrxiv.org/content/10.1101/2020.
06.09.20122036v1
78. Cervia C, Nilsson J, Zurbuchen Y, Valaperti A, Schreiner J, Wolfensberger A, et al. Systemic and
mucosal antibody secretion specific to SARS-CoV-2 during mild versus severe COVID-19. bioRxiv
[Preprint]. 2020; 2020.05.21.108308v1. Available from: https://www.biorxiv.org/content/10.1101/
2020.05.21.108308v1 PMID: 33221383
79. Reifer J, Hayum N, Heszkel B, Klagsbald I, Streva VA. SARS-CoV-2 IgG Antibody Responses in New
York City. medRxiv [Preprint]. 2020; 2020.05.23.20111427v2. Available from: https://www.medrxiv.
org/content/10.1101/2020.05.23.20111427v2 PMID: 32777699
80. He R, Lu Z, Zhang L, Fan T, Xiong R, Shen X, et al. The clinical course and its correlated immune sta-
tus in COVID-19 pneumonia. J Clin Virol. 2020; 127:104361. https://doi.org/10.1016/j.jcv.2020.
104361 PMID: 32344320
81. Laing AG, Lorenc A, Del Barrio IDM, Das A, Fish M, Monin L, et al. A consensus Covid-19 immune sig-
nature combines immuno-protection with discrete sepsis-like traits associated with poor prognosis.
medRxiv. 2020; 2020.06.08.20125112v1. Available from: https://www.medrxiv.org/content/10.1101/
2020.06.08.20125112v1
82. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients
with COVID-19 in Wuhan, China. Clin Infect Dis. 2020; 12. https://doi.org/10.1093/cid/ciaa248 PMID:
32161940
83. Bao J, Li C, Zhang K, Kang H, Chen W, Gu B. Comparative analysis of laboratory indexes of severe
and non-severe patients infected with COVID-19. Clin Chim Acta. 2020; https://doi.org/10.1016/j.cca.
2020.06.009 PMID: 32511971
84. Staines HM, Kirwan DE, Clark DJ, Adams ER, Augustin Y, Byrne RL, et al. Dynamics of IgG seroconver-
sion and pathophysiology of COVID-19 infections. medRxiv [Preprint]. 2020; 2020.06.07.20124636v2.
Available from: https://www.medrxiv.org/content/10.1101/2020.06.07.20124636v2
85. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, et al. Detection of Nucleocapsid
Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients.
medRxiv [Preprint] 2020; 2020.04.20.20071423v1. Available from: https://www.medrxiv.org/content/
10.1101/2020.04.20.20071423v1 PMID: 32511445
86. Solodky ML, Galvez C, Russias B, Detourbet P, N’Guyen-Bonin V, Herr A-L, et al. Lower detection
rates of SARS-COV2 antibodies in cancer patients vs healthcare workers after symptomatic COVID-
19. Ann Oncol. 2020;19–21.
87. Brotons C, Serrano J, Fernandez D, Garcia-Ramos C, Ichazo B, Lemaire J, et al. Seroprevalence
against COVID-19 and follow-up of suspected cases in primary health care in Spain. medRxiv [Pre-
print]. 2020; 2020.06.13.20130575v1. Available from: https://www.medrxiv.org/content/10.1101/2020.
06.13.20130575v1
88. Favara DM, Cooke A, Doffinger R, Houghton S, Budriunaite I, Bossingham S, et al. First results from
the UK COVID-19 Serology in Oncology Staff Study (CSOS). medRxiv [Preprint]. 2020;
2020.06.22.20136838v1. Available from: https://www.medrxiv.org/content/10.1101/2020.06.22.
20136838v1
89. Rudberg A-S, Havervall S, Manberg A, Falk AJ, Aguilera K, Ng H, et al. SARS-CoV-2 exposure, symp-
toms and seroprevalence in health care workers. medRxiv [Preprint]. 2020; 2020.06.22.20137646v1.
Available from: https://www.medrxiv.org/content/10.1101/2020.06.22.20137646v1
PLOS ONE Antibody response to SARS-CoV-2 infection in humans
PLOS ONE | https://doi.org/10.1371/journal.pone.0244126 December 31, 2020 21 / 27
90. Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of
asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26(8):1200–4 https://doi.org/10.1038/
s41591-020-0965-6 PMID: 32555424
91. Madariaga MLL, Guthmiller J, Schrantz S, Jansen M, Christenson C, Kumar M, et al. Clinical predic-
tors of donor antibody titer and correlation with recipient antibody response in a COVID-19 conva-
lescent plasma clinical trial. medRxiv [Preprint]. 2020; 2020.06.21.20132944v1. Available from:
https://www.medrxiv.org/content/10.1101/2020.06.21.20132944v1
92. Houlihan C, Vora N, Byrne T, Lewer D, Heaney J, Moore DA, et al. SARS-CoV-2 virus and antibodies
in front-line Health Care Workers in an acute hospital in London: preliminary results from a longitudinal
study. medRxiv [Preprint]. 2020; 2020.06.08.20120584v1. Available from: https://www.medrxiv.org/
content/10.1101/2020.06.08.20120584v1
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